Amended Current Report Filing (8-k/a)
January 28 2021 - 6:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K/A
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
December 7, 2020
SELLAS Life Sciences Group, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-33958
|
|
20-8099512
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
7 Times Square, Suite 2503
New York, NY 10036
|
|
|
(Address of Principal Executive Offices) (Zip Code)
|
Registrant’s telephone number, including area code: (917) 438-4353
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following
provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 par value per share
|
SLS
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Explanatory
Note
On December 10,
2020, SELLAS Life Sciences Group, Inc. (“SELLAS”) filed a Current Report on Form 8-K (the “Prior
8-K”) to report the entrance by SELLAS and SLSG Limited, LLC, a wholly-owned subsidiary of SELLAS (“SLSG,” and
collectively with SELLAS, the “Company”), into an Exclusive License Agreement (the “License Agreement”)
with 3D Medicines Inc. (“3DMed”) pursuant to which the Company granted 3D Med a sublicensable, royalty-bearing license,
under certain intellectual property owned or controlled by the Company, to develop, manufacture and have manufactured, and commercialize
the Company’s galinpepimut-S and heptavalent GPS product candidates. SELLAS is filing this amendment to the Prior 8-K in
order to file herewith, as Exhibit 10.1, the License Agreement. The Prior 8-K otherwise remains unchanged.
Item 9.01.
|
Financial Statements and Exhibits.
|
* Pursuant to Item 601(b)(10) of Regulation S-K, portions of
this exhibit have been omitted as the registrant has determined that the omitted information (i) is not material and (ii) would
likely cause competitive harm to the registrant if publicly disclosed.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
SELLAS LIFE SCIENCES GROUP, INC.
|
|
|
Date: January 27, 2021
|
/s/ Barbara A. Wood
|
|
Barbara A. Wood
|
|
Executive Vice President, General Counsel and Corporate Secretary
|
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Apr 2023 to Apr 2024